Copyright Reports & Markets. All rights reserved.

Global Acute Respiratory Distress Syndrome Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Acute Respiratory Distress Syndrome Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by Product
      • 1.4.2 Methylprednisolone
      • 1.4.3 Hydrocortisone
      • 1.4.4 Calf Pulmonary Surfactant for Injection
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Size Growth Rate by End User
      • 1.5.2 In-Patient
      • 1.5.3 Out-Patient
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Acute Respiratory Distress Syndrome Therapeutics Market Size
      • 2.1.1 Global Acute Respiratory Distress Syndrome Therapeutics Revenue 2014-2025
      • 2.1.2 Global Acute Respiratory Distress Syndrome Therapeutics Sales 2014-2025
    • 2.2 Acute Respiratory Distress Syndrome Therapeutics Growth Rate by Regions
      • 2.2.1 Global Acute Respiratory Distress Syndrome Therapeutics Sales by Regions
      • 2.2.2 Global Acute Respiratory Distress Syndrome Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Acute Respiratory Distress Syndrome Therapeutics Sales by Manufacturers
      • 3.1.1 Acute Respiratory Distress Syndrome Therapeutics Sales by Manufacturers
      • 3.1.2 Acute Respiratory Distress Syndrome Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Acute Respiratory Distress Syndrome Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Acute Respiratory Distress Syndrome Therapeutics Revenue by Manufacturers
      • 3.2.1 Acute Respiratory Distress Syndrome Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Acute Respiratory Distress Syndrome Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Acute Respiratory Distress Syndrome Therapeutics Price by Manufacturers
    • 3.4 Acute Respiratory Distress Syndrome Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Acute Respiratory Distress Syndrome Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Acute Respiratory Distress Syndrome Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Acute Respiratory Distress Syndrome Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Acute Respiratory Distress Syndrome Therapeutics Sales by Product
    • 4.2 Global Acute Respiratory Distress Syndrome Therapeutics Revenue by Product
    • 4.3 Acute Respiratory Distress Syndrome Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Acute Respiratory Distress Syndrome Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Acute Respiratory Distress Syndrome Therapeutics by Countries
      • 6.1.1 North America Acute Respiratory Distress Syndrome Therapeutics Sales by Countries
      • 6.1.2 North America Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Acute Respiratory Distress Syndrome Therapeutics by Product
    • 6.3 North America Acute Respiratory Distress Syndrome Therapeutics by End User

    7 Europe

    • 7.1 Europe Acute Respiratory Distress Syndrome Therapeutics by Countries
      • 7.1.1 Europe Acute Respiratory Distress Syndrome Therapeutics Sales by Countries
      • 7.1.2 Europe Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Acute Respiratory Distress Syndrome Therapeutics by Product
    • 7.3 Europe Acute Respiratory Distress Syndrome Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Acute Respiratory Distress Syndrome Therapeutics by Countries
      • 8.1.1 Asia Pacific Acute Respiratory Distress Syndrome Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Acute Respiratory Distress Syndrome Therapeutics by Product
    • 8.3 Asia Pacific Acute Respiratory Distress Syndrome Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Acute Respiratory Distress Syndrome Therapeutics by Countries
      • 9.1.1 Central & South America Acute Respiratory Distress Syndrome Therapeutics Sales by Countries
      • 9.1.2 Central & South America Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Acute Respiratory Distress Syndrome Therapeutics by Product
    • 9.3 Central & South America Acute Respiratory Distress Syndrome Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics by Countries
      • 10.1.1 Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics by Product
    • 10.3 Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics by End User

    11 Company Profiles

    • 11.1 Therabron Therapeutics, Inc.
      • 11.1.1 Therabron Therapeutics, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Therabron Therapeutics, Inc. Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.1.5 Therabron Therapeutics, Inc. Recent Development
    • 11.2 Serendex Pharmaceuticals A/S
      • 11.2.1 Serendex Pharmaceuticals A/S Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Serendex Pharmaceuticals A/S Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.2.5 Serendex Pharmaceuticals A/S Recent Development
    • 11.3 Silence Therapeutics Plc
      • 11.3.1 Silence Therapeutics Plc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Silence Therapeutics Plc Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.3.5 Silence Therapeutics Plc Recent Development
    • 11.4 Histocell S.L.
      • 11.4.1 Histocell S.L. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Histocell S.L. Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.4.5 Histocell S.L. Recent Development
    • 11.5 Altor BioScience Corporation
      • 11.5.1 Altor BioScience Corporation Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Altor BioScience Corporation Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.5.5 Altor BioScience Corporation Recent Development
    • 11.6 Athersys, Inc.
      • 11.6.1 Athersys, Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Athersys, Inc. Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.6.5 Athersys, Inc. Recent Development
    • 11.7 Faron Pharmaceuticals Oy
      • 11.7.1 Faron Pharmaceuticals Oy Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Faron Pharmaceuticals Oy Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.7.5 Faron Pharmaceuticals Oy Recent Development
    • 11.8 FirstString Research, Inc.
      • 11.8.1 FirstString Research, Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 FirstString Research, Inc. Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.8.5 FirstString Research, Inc. Recent Development
    • 11.9 GlaxoSmithKline Plc
      • 11.9.1 GlaxoSmithKline Plc Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 GlaxoSmithKline Plc Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.9.5 GlaxoSmithKline Plc Recent Development
    • 11.10 Phylogica Limited
      • 11.10.1 Phylogica Limited Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Phylogica Limited Acute Respiratory Distress Syndrome Therapeutics Products Offered
      • 11.10.5 Phylogica Limited Recent Development

    12 Future Forecast

    • 12.1 Acute Respiratory Distress Syndrome Therapeutics Market Forecast by Regions
      • 12.1.1 Global Acute Respiratory Distress Syndrome Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Acute Respiratory Distress Syndrome Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Acute Respiratory Distress Syndrome Therapeutics Market Forecast by Product
      • 12.2.1 Global Acute Respiratory Distress Syndrome Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Acute Respiratory Distress Syndrome Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Acute Respiratory Distress Syndrome Therapeutics Market Forecast by End User
    • 12.4 North America Acute Respiratory Distress Syndrome Therapeutics Forecast
    • 12.5 Europe Acute Respiratory Distress Syndrome Therapeutics Forecast
    • 12.6 Asia Pacific Acute Respiratory Distress Syndrome Therapeutics Forecast
    • 12.7 Central & South America Acute Respiratory Distress Syndrome Therapeutics Forecast
    • 12.8 Middle East and Africa Acute Respiratory Distress Syndrome Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Acute Respiratory Distress Syndrome Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Acute Respiratory Distress Syndrome Therapeutics market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acute Respiratory Distress Syndrome Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Acute Respiratory Distress Syndrome Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acute Respiratory Distress Syndrome Therapeutics in these regions.
      This research report categorizes the global Acute Respiratory Distress Syndrome Therapeutics market by top players/brands, region, type and end user. This report also studies the global Acute Respiratory Distress Syndrome Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Therabron Therapeutics, Inc.
      Serendex Pharmaceuticals A/S
      Silence Therapeutics Plc
      Histocell S.L.
      Altor BioScience Corporation
      Athersys, Inc.
      Faron Pharmaceuticals Oy
      FirstString Research, Inc.
      GlaxoSmithKline Plc
      Phylogica Limited

      Market size by Product
      Methylprednisolone
      Hydrocortisone
      Calf Pulmonary Surfactant for Injection
      Others
      Market size by End User
      In-Patient
      Out-Patient

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Acute Respiratory Distress Syndrome Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Acute Respiratory Distress Syndrome Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Acute Respiratory Distress Syndrome Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Acute Respiratory Distress Syndrome Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Acute Respiratory Distress Syndrome Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acute Respiratory Distress Syndrome Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now